FDA Set to Decide on Two Likely Blockbuster Drugs By Sanofi Genzyme

The second of two potential drugs for immune system disorders that are together expected to bring in peak annual revenues of between $3 billion and $7 billion to Sanofi Genzyme and a New York based partner in the next few years is expected to have a decision on U.S. approval by next spring.

Both drugs are partnered between the Cambridge-based division of Sanofi (NYSE: SNY) that’s focused on specialty pharmaceuticals (formerly called simply Genzyme), and Tarrytown, N.Y.-based Regeneron Pharmaceuticals (Nasdaq: REGN).

Back to news